SK Biopharmaceuticals to Operate First Independent Booth at World's Largest Bio Industry Exhibition, "BIO USA"

On June 12, SK Biopharmaceuticals announced that it will participate in the "2025 BIO International Convention" (hereafter BIO USA), which will be held in Boston, United States, from June 16 to 19. For the first time, SK Biopharmaceuticals will operate its own independent booth at the event and plans to accelerate its efforts to expand its business and discover new partnerships in the global market.

BIO USA is the world's largest biotechnology exhibition, organized by the Biotechnology Innovation Organization in the United States. It serves as a key stage for the global bioindustry, bringing together more than 20,000 industry professionals from over 65 countries to explore promising technologies and collaboration opportunities.

SK Biopharmaceuticals aims to enhance its brand image and credibility among global pharmaceutical and biotech industry stakeholders, and will actively seek new collaboration opportunities through one-on-one business meetings and booth exhibitions. The booth design features SK Biopharmaceuticals' signature orange as an accent color and utilizes gentle curves to ensure visibility from all directions, expressing both accessibility and customer-friendliness.

At this exhibition, SK Biopharmaceuticals will present its philosophy of innovation aimed at improving patients' quality of life from multiple perspectives, under the slogan "SK, For Patients, For Life," with "patient-centricity" as its core value. In particular, the company will highlight the global expansion potential of cenobamate, its innovative epilepsy drug, by sharing its successful experience in the U.S. market.

Since its U.S. launch in 2020, cenobamate has quickly established itself in the market, surpassing 170,000 cumulative prescribed patients as of the first half of this year and continuing its growth trajectory. The company is expanding brand awareness and treatment accessibility through synergy with its large-scale direct-to-consumer (DTC) advertising campaign currently underway across the United States. At the local BIO USA exhibition booth, SK Biopharmaceuticals will showcase the DTC advertisement video and real patient case videos, aiming to further solidify its presence in the global market.

Lee Donghoon, CEO of SK Biopharmaceuticals, stated, "BIO USA is an important opportunity to present SK Biopharmaceuticals' achievements and vision in the global market, as well as a platform to seek new growth opportunities. Going forward, we will continue to prioritize patient-centric innovation and expand treatment solutions that can benefit more patients."